002566.SHE Jilin Jian Yisheng Pharmaceutical Co Ltd
- Market cap
- CNY 1.97B
- P/E
- 74.5x
- P/B
- 0.89x
- ROE
- 1.3%
- Dividend yield
- 2.31%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002566.SHE undervalued?
Graham number002566.SHE trades 71.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jilin Jian Yisheng Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jilin Jian Yisheng Pharmaceutical Co Ltd yet.
Jilin Jian Yisheng Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jilin Jian Yisheng Pharmaceutical Co Ltd
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprising acai collagen solid drinks, multivitamin mineral tablets, collagen peptide juice drinks, and fruit lemo…
Full company profileJilin Jian Yisheng Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jilin Jian Yisheng Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 939M | 1.03B | 975M | 1.01B | 843M | 878M | 830M | 854M | 668M | 640M | 580M |
| Gross Profit | 659M | 748M | 736M | 753M | 625M | 657M | 615M | 629M | 494M | 474M | 421M |
| Operating Income | 8.04M | 101M | 107M | 111M | 110M | 129M | 103M | 116M | 61.4M | 38.8M | 43.8M |
| EBITDA | 96.6M | 165M | 163M | 168M | 159M | 177M | 155M | 171M | 116M | 85.4M | 40.3M |
| Net Income | 13.2M | 60.1M | 69.1M | 76.6M | 80.1M | 96.0M | 83.1M | 94.7M | 52.1M | 29.0M | 28.3M |
| EPS | 0.04 | 0.18 | 0.21 | 0.23 | 0.24 | 0.29 | 0.25 | 0.29 | 0.16 | 0.09 | 0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 2.67B | 2.65B | 2.55B | 2.50B | 2.80B | 2.86B | 2.97B | 3.05B | 2.97B | 2.96B | 2.97B |
| Total Liabilities | 870M | 756M | 587M | 439M | 664M | 666M | 717M | 714M | 637M | 630M | 647M |
| Shareholders' Equity | 1.74B | 1.80B | 1.86B | 1.93B | 2.00B | 2.08B | 2.15B | 2.23B | 2.24B | 2.23B | 2.23B |
| Cash & Short-term Investments | 79.9M | 80.6M | 38.8M | 63.0M | 287M | 290M | 403M | 591M | 531M | 63.6M | 85.1M |
| Total Debt | 712M | 541M | 441M | 293M | 418M | 415M | 444M | 474M | 446M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.5M | 271M | 167M | 211M | 204M | 215M | 146M | 209M | 58.9M | 98.7M | - |
| Capital Expenditure | 54.4M | 83.5M | 73.7M | 21.7M | 75.9M | 107M | 41.4M | 35.8M | 15.9M | 13.6M | 2.67M |
| Free Cash Flow | -71.9M | 187M | 93.6M | 189M | 128M | 108M | 104M | 173M | 43.0M | 85.1M | 38.3M |
| Ratios | |||||||||||
| ROE | 0.8% | 3.3% | 3.7% | 4.0% | 4.0% | 4.6% | 3.9% | 4.2% | 2.3% | 1.3% | 1.3% |
| ROA | 0.5% | 2.3% | 2.7% | 3.1% | 2.9% | 3.4% | 2.8% | 3.1% | 1.8% | 1.0% | 1.0% |
| Net Profit Margin | 1.4% | 5.8% | 7.1% | 7.6% | 9.5% | 10.9% | 10.0% | 11.1% | 7.8% | 4.5% | 4.9% |
| Debt to Equity | 0.41x | 0.30x | 0.24x | 0.15x | 0.21x | 0.20x | 0.21x | 0.21x | 0.20x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jilin Jian Yisheng Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.31%
- Forward dividend
- 0.08 CNY
- Payout ratio
- 157.3%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 45.6M | 0.14 | 157.3% |
| 2024 | CNY 61.6M | 0.19 | 118.3% |
| 2023 | CNY 29.9M | 0.09 | 31.5% |
| 2022 | CNY 9.93M | 0.03 | 11.9% |
| 2021 | CNY 9.93M | 0.03 | 10.3% |
| 2020 | CNY 16.5M | 0.05 | 20.7% |
| 2019 | CNY 17.2M | 0.05 | 22.5% |
| 2018 | CNY 39.2M | 0.12 | 56.8% |
| 2017 | CNY 28.2M | 0.09 | 46.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on May 22, 2014.
Who owns Jilin Jian Yisheng Pharmaceutical Co Ltd
- Insiders 48.36%
- Institutions 4.78%
- Public & others 46.85%
- Shares outstanding 331M
- Free float 187M
Jilin Jian Yisheng Pharmaceutical Co Ltd company profile
- Company name
- Jilin Jian Yisheng Pharmaceutical Co Ltd
- Ticker
- 002566.SHE
- ISIN
- CNE1000011C3
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 18, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,656
- Fiscal year end
- December
- Address
- No. 17-20 Wenhua East Road, Ji'an, China, 134200
- Phone
- 86 43 5622 2471
- Website
- yisheng-pharm.com
About Jilin Jian Yisheng Pharmaceutical Co Ltd
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprising acai collagen solid drinks, multivitamin mineral tablets, collagen peptide juice drinks, and fruit lemon powder. It is also involved in pharmaceutical contract manufacturing; production of health food, food, health care products; special medical products; production of fertilizers and beverages; sale of food through the internet; planting and production of Chinese medicinal herbs extracts; wholesale and retail of cosmetics; road freight transportation; research and development of bio-organic and microbial fertilizers; non-residential real estate, machinery, and equipment leasing; packaging printing; paper cutting and sales; development and application of human stem cell technology; and the traditional spice products business. In addition, the company provides life beauty services; Chinese medicine health and wellness services; and technical development, consulting, exchange, promotion, and transfer services. Jilin Jian Yisheng Pharmaceutical Co., Ltd. was founded in 1997 and is headquartered in Ji'an, China.
Jilin Jian Yisheng Pharmaceutical Co Ltd management
5- Mr. Xiaomin XueGeneral Manager · born 1958
- Mr. Jian Tao BiDeputy GM, CFO & Non-Independent Director · born 1970
- Mr. Tiejun LiDeputy GM & Secretary of the Board · born 1960
- Mr. Wei MengDeputy General Manager · born 1973
- Meihua SuAccounting Supervisor